Preclinical mitigation of 5-HT2B agonism-related cardiac valvulopathy revisited
{{output}}
Cardiac valvulopathy (Cardiac Valve Disease; CVD) associated with off-target activation of the 5-hydroxytryptamine (5-HT) 2B receptor has been well recognized, but is still poorly predicted during drug development. The regulatory guidance proposes the use of 5... ...